Advanced search
1 file | 494.86 KB

Secukinumab : IL-17A inhibition to treat psoriatic arthritis

Reinhart Speeckaert (UGent) , Nanja van Geel (UGent) , Jo Lambert (UGent) , L Claeys, Joris Delanghe (UGent) and Marijn Speeckaert (UGent)
(2017) DRUGS OF TODAY. 52(11). p.607-616
Author
Organization
Abstract
Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1 kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.
Keywords
bDMARDs, IL-17A, Psoriatic arthritis, Secukinumab, Monoclonal antibodies, Psoriasis, COLLAGEN-INDUCED ARTHRITIS, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, RANDOMIZED CONTROLLED-TRIAL, NECROSIS-FACTOR-ALPHA, DOUBLE-BLIND, CARTILAGE DESTRUCTION, JOINT INFLAMMATION, PLAQUE PSORIASIS, BONE EROSION, EULAR RECOMMENDATIONS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 494.86 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Speeckaert, Reinhart, Nanja van Geel, Jo Lambert, L Claeys, Joris Delanghe, and Marijn Speeckaert. 2017. “Secukinumab : IL-17A Inhibition to Treat Psoriatic Arthritis.” Drugs of Today 52 (11): 607–616.
APA
Speeckaert, R., van Geel, N., Lambert, J., Claeys, L., Delanghe, J., & Speeckaert, M. (2017). Secukinumab : IL-17A inhibition to treat psoriatic arthritis. DRUGS OF TODAY, 52(11), 607–616.
Vancouver
1.
Speeckaert R, van Geel N, Lambert J, Claeys L, Delanghe J, Speeckaert M. Secukinumab : IL-17A inhibition to treat psoriatic arthritis. DRUGS OF TODAY. 2017;52(11):607–16.
MLA
Speeckaert, Reinhart, Nanja van Geel, Jo Lambert, et al. “Secukinumab : IL-17A Inhibition to Treat Psoriatic Arthritis.” DRUGS OF TODAY 52.11 (2017): 607–616. Print.
@article{8525102,
  abstract     = {Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1 kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.},
  author       = {Speeckaert, Reinhart and van Geel, Nanja and Lambert, Jo and Claeys, L and Delanghe, Joris and Speeckaert, Marijn},
  issn         = {1699-3993},
  journal      = {DRUGS OF TODAY},
  keyword      = {bDMARDs,IL-17A,Psoriatic arthritis,Secukinumab,Monoclonal antibodies,Psoriasis,COLLAGEN-INDUCED ARTHRITIS,ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY,RANDOMIZED CONTROLLED-TRIAL,NECROSIS-FACTOR-ALPHA,DOUBLE-BLIND,CARTILAGE DESTRUCTION,JOINT INFLAMMATION,PLAQUE PSORIASIS,BONE EROSION,EULAR RECOMMENDATIONS},
  language     = {eng},
  number       = {11},
  pages        = {607--616},
  title        = {Secukinumab : IL-17A inhibition to treat psoriatic arthritis},
  url          = {http://dx.doi.org/10.1358/dot.2016.52.11.2526754},
  volume       = {52},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: